FDA — authorised 15 May 2020
- Application: NDA213973
- Marketing authorisation holder: DECIPHERA PHARMS
- Local brand name: QINLOCK
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 DCC-2618 in United States
FDA authorised DCC-2618 on 15 May 2020
Marketing authorisation
DCC-2618 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is DCC-2618 approved in United States?
Yes. FDA authorised it on 15 May 2020.
Who is the marketing authorisation holder for DCC-2618 in United States?
DECIPHERA PHARMS holds the US marketing authorisation.